Instrument Inactif

Communiqués Algeta ASA

Actions

ALGETA

NO0010239437

Recherche biotechnologique et médicale

Communiqués

18/11/13	Algeta ASA : Algeta to host Capital Markets Days	PU
08/11/13	Algeta ASA : Algeta's Financial Calendar 2014	PU
08/11/13	Algeta ASA : CORRECTION: Algeta ASA : Algeta Results for the Third Quarter 2013	PU
05/11/13	Algeta ASA : Algeta to Participate in Upcoming Investor Conferences	PU
28/10/13	Algeta ASA : Algeta Schedules Third Quarter 2013 Results Presentation, Webcast and Conference Call	PU
12/09/13	Algeta ASA : New data and analyses from the phase III ALSYMPCA trial of radium Ra 223 dichloride to be presented at the European Cancer Congress (ECCO-ESMO-ESTRO) 2013	PU
28/08/13	Algeta ASA : Algeta results for the First Half and Second Quarter 2013	PU
19/08/13	Algeta ASA : Algeta schedules first half and second quarter 2013 results presentation, webcast and conference call	PU
19/08/13	Algeta ASA : Algeta Appoints Dr Andreas Menrad as Chief Scientific Officer	PU
12/08/13	Algeta ASA : Algeta to Participate in Upcoming Investor Conferences	PU
20/06/13	Algeta ASA : Algeta celebrates the official opening of its commercial production facility for Xofigo® (radium Ra 223 dichloride) at the Institute for Energy Technology (IFE) in Norway	PU
11/06/13	Algeta ASA : Algeta to evaluate novel Targeted Thorium Conjugate (TTC) based on Avipep's Avibody platform	PU
30/05/13	Algeta ASA : Algeta announces first sale of Xofigo® (radium Ra 223 dichloride) in the United States	PU
16/05/13	Algeta ASA : New data and analyses from clinical trials of Xofigo® (radium-223 dichloride) to be presented at ASCO	PU
15/05/13	Algeta ASA : Algeta announces that Xofigo® (radium-223 dichloride) has been approved by the US FDA	PU
15/05/13	Algeta ASA : Algeta results for the first quarter 2013	PU
14/05/13	Algeta ASA : Algeta to Participate in Upcoming Investor Conferences	PU
07/05/13	Algeta ASA : Algeta schedules first quarter 2013 results presentation, webcast and conference call	PU
02/05/13	Algeta ASA : Algeta exercises option and signs exclusive license agreement with Lumiphore, Inc. for novel technology for development of Targeted Thorium Conjugates (TTCs)	PU
17/04/13	Algeta ASA : Algeta to Participate in Upcoming Investor Conference	PU
20/03/13	Algeta ASA : Algeta - Notice of Annual General Meeting 2013	PU
20/02/13	Algeta ASA : Algeta to Participate in Upcoming Investor Conferences	PU
28/01/13	Algeta ASA : Algeta initiates new oncology research program to evaluate the potential of a Targeted Thorium Conjugate (TTC) based on Immunomedics' anti-CD22 monoclonal antibody	PU
14/12/12	Algeta ASA : Algeta's partner Bayer submits New Drug Application to US FDA for Radium-223 Dichloride for the Treatment of Castration-Resistant Prostate Cancer with Bone Metastases	PU
12/12/12	Algeta ASA : Algeta's partner Bayer submits Radium-223 Dichloride for EU Marketing Authorisation for the Treatment of Castration-Resistant Prostate Cancer with Bone Metastases	PU